Sanofi-Aventis finalized a deal worth about $20.1 billion to take over Genzyme. The acquisition, which gives Sanofi access to Genzyme's orphan-drug business, will be partly funded through a $7 billion note offering.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||